Overview

Open-Label, Extension Study to 810P202

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

Open-label, extension study for subjects that completed 810P202 to examine long term safety and tolerability of repeated dosing of SPN-810M as an adjunctive therapy in children with Impulsive Aggression Comorbid with Attention-Deficit/Hyperactivity Disorder (ADHD).

Phase:

Phase 2

Details

Lead Sponsor:

Supernus Pharmaceuticals, Inc.

Treatments:

Molindone